
Opinion|Videos|December 23, 2024
Navigating HER2 Heterogeneity: Precision Pathways in Breast Cancer Treatment
A panelist discusses how differences in HER2-positive, HER2-low, and HER2-negative status impact clinical decision-making.
Advertisement
Episodes in this series

Now Playing
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
Modern Therapies Challenge Radiation’s Role in Early Breast Cancer Survival
3
FDA Approves Lumateperone With Antidepressant Use for Major Depressive Disorder
4
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
5











































































































































































































